doxorubicin plus cyclophosphamide followed by docetaxel plus trastuzumab
Comparator:
vs docetaxel plus carboplatin with trastuzumab followed by trastuzumab; vs doxorubicin plus cyclophosphamide followed by docetaxel;
Risk of bias:
low;
some concerns;
high;
NA;